Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT06575036
PHASE2

Sugammadex Dose Finding Under Two Years Old

Sponsor: Sang-Hwan Ji

View on ClinicalTrials.gov

Summary

This is a prospective dose-finding study of sugammadex for conventional reversal of rocuronium-induced neuromuscular blockade in children under two years of age. This study will explore 50% effective dose and 95% effective dose of sugammadex for reversal of neuromuscular blockade in less than two minutes under biased coin up-and-down method.

Official title: Reversal of Rocuronium-induced Neuromuscular Blockade by Sugammadex in Children Younger Than 2 Years Old: a Prospective Dose Finding Study

Key Details

Gender

All

Age Range

Any - 23 Months

Study Type

INTERVENTIONAL

Enrollment

33

Start Date

2024-09-15

Completion Date

2025-05-31

Last Updated

2024-08-29

Healthy Volunteers

No

Interventions

DRUG

Sugammadex

The starting dose of sugammadex will be 0.5mg/kg. When the dose for a patient was not effective, the dose for next patient will be increased by 0.5mg/kg. When the dose was effective, the dose for next patient will be decreased by 0.5mg/kg or maintained, with a 1:1 of allocation ratio.

Locations (1)

Seoul National University Hospital

Seoul, South Korea